Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28498977 | 0.82 | KIF11 (0.40) | RIPK1KIF11LMNAGRM2GRM3 | |
| SCHEMBL23344877 | 0.81 | RIPK1 (0.53) | RIPK1LMNAMAPT | |
| SCHEMBL15745582 | 0.81 | MAPT (0.44) | LMNAMAPT | |
| SCHEMBL13028672 | 0.81 | MAPT (0.44) | LMNAMAPT | |
| SCHEMBL16449781 | 0.81 | MAPT (0.44) | LMNAMAPT | |
| SCHEMBL13594310 | 0.80 | RIPK1 (0.51) | RIPK1LMNA | |
| Hydrochloric Acid SCHEMBL28712260 | 0.80 | NAAA (0.43) | KIF11MAPT | |
| SCHEMBL13305755 | 0.79 | CYP2C19 (0.42) | LMNAMAPT | |
| SCHEMBL25512616 | 0.79 | RIPK1 (0.50) | RIPK1LMNAMAPT | |
| SCHEMBL28864342 | 0.76 | RIPK1 (0.51) | RIPK1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | RIPK1 4670/4885KIF11 4588/4885LMNA 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.